Belvedere Trading’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Belvedere Trading’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4,193	Closed	-$428K	–	1066
2023 Q2	$428K	Sell	4,193 -558	-12%	-$52.8K	﹤0.01%	165
2023 Q1	$432K	Sell	4,751 -1,960	-29%	-$115K	﹤0.01%	171
2022 Q4	$255K	Sell	6,711 -1,792	-21%	-$61.7K	﹤0.01%	267
2022 Q3	$279K	Sell	8,503 -4,844	-36%	-$134K	0.01%	116
2022 Q2	$470K	Buy	13,347 +10,879	+441%	+$325K	0.02%	91
2022 Q1	$78K	Buy	+2,468	New	+$73.2K	﹤0.01%	357

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Belvedere Trading's RETA Position: Q3 2023 in Review

Belvedere Trading sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 4,193 shares — an estimated $428K sold.

Belvedere Trading first reported a position in RETA in Q1 2022 and held it in 6 quarters. The position peaked at $470K in Q2 2022. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Belvedere Trading reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Belvedere Trading sold 4,193 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $428K.
Belvedere Trading first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2022 and held it in 6 quarters.
Belvedere Trading's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $470K in Q2 2022.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Belvedere Trading's 13F filing for Q3 2023, filed 27 Oct 2023.